Steroid therapy for Graves ophthalmopathy
DOI:
https://doi.org/10.12923/cipms-2025-0025Keywords:
Graves disease, Graves ophthalmopathy, steroids, glucocorticoidsAbstract
Graves' disease (GD) is a prevalent autoimmune disorder primarily affecting the thyroid gland, but it also impacts other organs, notably the eyes. Graves' ophthalmopathy (GO), an autoimmune condition associated with GD, affects the tissues behind the eyes, leading to inflammation and tissue remodeling. Risk factors for GO include radioactive iodine therapy, untreated hyperthyroidism, smoking and high serum TSH-receptor antibody levels. Management strategies involve various approaches, including pharmacological treatments such as glucocorticoids. High-dose systemic glucocorticoids are particularly effective in treating moderate to severe and active GO. This review was undertaken to consolidate current evidence on steroid therapy for GO, exploring the nuances of different administration routes, dosages and the potential need for second-line treatments. By providing a comprehensive analysis of the existing literature, this review aims to enhance clinicians' understanding of steroid therapy in GO, highlight gaps in current knowledge, and propose areas for future research.
References
1. Graves' disease: Introduction, epidemiology, endogenous and environmental pathogenic factors. Ann Endocrinol (Paris). 2018;79: 599-607.
2. Smith TJ, Hegedüs L. Graves' Disease. N Engl J Med. 2016;375: 1552-65.
3. Hussain YS, Hookham JC, Allahabadia A, Balasubramanian SP. Epidemiology, management and outcomes of Graves' disease-real life data. Endocrine. 2017;56:568-78.
4. Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018;14:301-16.
5. Perros P, Neoh C, Dickinson J. Thyroid eye disease. BMJ.2009;338: b560.
6. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid. 2002;12:855-60.
7. Bahn RS. Current insights into the pathogenesis of Graves’ ophthalmopathy. Horm Metab Res. 2015;47:773-8.
8. Huang Y, Fang S, Li D, Zhou H, Li B, Fan X. The involvement of T cell pathogenesis in thyroid-associated ophthalmopathy. Eye (Lond). 2019;33:176-82.
9. Bahn RS. Graves' ophthalmopathy. N Engl J Med. 2010;362:726-38.
10. Bartalena L, Marcocci C, Pinchera A. Graves’ ophthalmopathy: a preventable disease?. Eur J Endocrinol. 2002;146:457.
11. Fang S, Huang Y, Zhong S, Li Y, Zhang Y, Li Y, et al. Regulation of Orbital Fibrosis and Adipogenesis by Pathogenic Th17 Cells in Graves Orbitopathy. J Clin Endocrinol Metab. 2017;102:4273-83.
12. Wei H, Guan M, Qin Y, Xie C, Fu X, Gao F, et al. Circulating levels of miR-146a and IL-17 are significantly correlated with the clinical activity of Graves’ ophthalmopathy. Endocr J. 2014;61:1087-92.
13. Fang S, Huang Y, Wang S, Zhang Y, Luo X, Liu L, et al. IL-17A Exacerbates fibrosis by promoting the proinflammatory and profibrotic function of orbital fibroblasts in TAO. J Clin Endocrinol Metab. 2016;101:2955-65.
14. Fang S, Huang Y, Zhong S, Zhang Y, Liu X, Wang Y, et al. IL-17A Promotes RANTES expression, but not IL-16, in orbital fibroblasts Via CD40-CD40L combination in thyroid-associated ophthalmopathy. Investig Opthalmol Vis Sci. 2016;57:6123-33.
15. Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML. Epidemiology, natural history, risk factors, and prevention of Graves' orbitopathy. Front Endocrinol (Lausanne). 2020;11:615993.
16. Dik WA, Virakul S, van Steensel L. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy. Exp Eye Res. 2016;142:83-91.
17. Smith TJ, Hegedüs L, Lesser I, Perros P, Dorris K, Kinrade M, et al. How patients experience thyroid eye disease. Front Endocrinol. 2023;14:1283374.
18. Qian L, Wei W. Identified risk factors for dry eye syndrome: a systematic review and meta-analysis. PLoS ONE. 2022;17:e0271267.
19. Park J, Baek S. Dry eye syndrome in thyroid eye disease patients: the role of increased incomplete blinking and meibomian gland Loss. Acta Ophthalmol. 2019;97:800-6.
20. Lo C, Yang M, Rootman D. Natural history of inflammatory and non-inflammatory dry eye in thyroid eye disease. Orbit. 2021;40:389-93.
21. Liao X, Lai KKH, Aljufairi FMAA, Chen W, Hu Z, Wong HYM, et al. Ocular surface changes in treatment-naive thyroid eye disease. J Clin Med. 2023;12:3066.
22. Rana HS, Akella SS, Clabeaux CE, Skurski ZP, Aakalu VK. Ocular surface disease in thyroid eye disease: a narrative review. Ocul Surf. 2022;24:67-73.
23. Jones L, Downie LE, Korb D, Benitez-del-Castillo JM, Dana R, Deng SX, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15:575-628.
24. Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, et al. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol. 2021;185:G43-G67.
25. Eckstein AK, Plicht M, Lax H, Neuhäuser M, Mann K, Lederbogen S, et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006;91:3464-70.
26. Douglas RS, Afifiyan NF, Hwang CJ, Chong K, Haider U, Richards P, et al. Increased generation of fibrocytes in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2010;95:430-8.
27. Terwee CB, Prummel MF, Gerding MN, Kahaly GJ, Dekker FW, Wiersinga WM. Measuring disease activity to predict therapeutic outcome in Graves' ophthalmopathy. Clin Endocrinol (Oxf). 2005;62:145-55.
28. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Tørring O. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol. 2008;158:69-75.
29. Kahaly GJ, Wüster C, Olivo PD, Diana T. High titers of thyrotropin receptor antibodies are associated with orbitopathy in patients with Graves disease. J Clin Endocrinol Metab. 2019;104:2561-8.
30. Perros P, Dayan CM, Dickinson AJ, Ezra D, Estcourt S, Foley P, et al. Management of patients with Graves' orbitopathy: initial assessment, management outside specialised centres and referral pathways. Clin Med (Lond). 2015;15:173-8.
31. Hiromatsu Y, Eguchi H, Tani J, Kasaoka M, Teshima Y. Graves' ophthalmopathy: epidemiology and natural history. Intern Med. 2014;53:353-60.
32. European Group on Graves' Orbitopathy (EUGOGO); Wiersinga WM, Perros P, Kahaly GJ, Mourits MP, Baldeschi L, et al. Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol. 2006;155:387-9.
33. Patel A, Yang H, Douglas RS. A new era in the treatment of thyroid eye disease. Am J Ophthalmol. 2019;208:281-8.
34. Tu X, Dong Y, Zhang H, Su Q. Corticosteroids for Graves' ophthalmopathy: Systematic review and meta-analysis. Biomed Res Int. 2018;2018:4845894.
35. Wiersinga WM. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy. Lancet Diabetes Endocrinol. 2017;5:134-42.
36. Zang S, Ponto KA, Kahaly GJ. Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011;96:320-32.
37. Riedl M, Kolbe E, Kampmann E, Krämer I, Kahaly GJ. Prospectively recorded and MedDRA-coded safety data of intravenous methylprednisolone therapy in Graves' orbitopathy. J Endocrinol Invest. 2015;38:177-82.
38. Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, Single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab. 2005;90:5234-40.
39. Bartalena L, Krassas GE, Wiersinga W, Marcocci C, Salvi M, Daumerie C, et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. J Clin Endocrinol Metab. 2012;97:4454-63.
40. Hoppe E, Lee ACH, Hoppe D, Kahaly GJ. Predictive factors for changes in quality of life after steroid treatment for active moderate-to-severe Graves' orbitopathy: A prospective trial. Eur Thyroid J. 2021;9:313-20.
41. Sisti E, Coco B, Menconi F, Leo M, Rocchi R, Latrofa F, et al. Age and dose are major risk factors for liver damage associated with intravenous glucocorticoid pulse therapy for Graves' orbitopathy. Thyroid. 2015;25:846-50.
42. Miśkiewicz P, Jankowska A, Brodzińska K, Milczarek-Banach J, Ambroziak U. Influence of methylprednisolone pulse therapy on liver function in patients with Graves' orbitopathy. Int J Endocrinol. 2018;2018:1978590.
43. Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158:273-85.
44. Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, et al. The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. Eur Thyroid J. 2016;5:9-26.
45. Kahaly GJ. Management of Graves thyroidal and extrathyroidal disease: An update. J Clin Endocrinol Metab. 2020;105:3704-20.
46. Marcocci C, Watt T, Altea MA, Rasmussen AK, Feldt-Rasmussen U, Orgiazzi J, et al. Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association. Eur J Endocrinol. 2012;166:247-53.
47. Currò N, Covelli D, Vannucchi G, Campi I, Pirola G, Simonetta S, et al. Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy. Thyroid. 2014;24:897-905.
48. Längericht J, Krämer I, Kahaly GJ. Glucocorticoids in Graves' orbitopathy: mechanisms of action and clinical application. Ther Adv Endocrinol Metab. 2020;11:2042018820958335.
49. Bartalena L, Veronesi G, Krassas GE, Wiersinga WM, Marcocci C, Marinò M, et al. Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy? J Endocrinol Invest. 2017;40:547-53.
50. Nedeljkovic Beleslin B, Ciric J, Stojkovic M, Savic S, Lalic T, Stojanovic M, et al. Comparison of efficacy and safety of parenteral versus parenteral and oral glucocorticoid therapy in Graves' orbitopathy. Int J Clin Pract. 2020;74:e13608.
51. Lee SJ, Rim TH, Jang SY, Kim CY, Shin DY, Lee EJ, et al. Treatment of upper eyelid retraction related to thyroid-associated ophthalmopathy using subconjunctival triamcinolone injections. Graefes Arch Clin Exp Ophthalmol. 2013;251:261-70.
52. Huebert I, Heinicke N, Kook D, Boost KA, Miller CV, Mayer WJ, et al. Dual platelet inhibition in cases of severe retrobulbar hemorrhage following retrobulbar and peribulbar anesthesia. J Cataract Refract Surg. 2015;41:2092-101.
53. Ebner R, Devoto MH, Weil D, Bordaberry M, Mir C, Martinez H, et al. Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol. 2004;88: 1380-6.
54. Goldberg RA. Orbital steroid injections. Br J Ophthalmol. 2004;88: 1359-60.
55. Lanzolla G, Maglionico MN, Comi S, Menconi F, Piaggi P, Posarelli C, et al. Sirolimus as a second-line treatment for Graves' orbitopathy. J Endocrinol Invest. 2022;45:2171-80.
56. Roos JCP, Murthy R. Sirolimus (rapamycin) for the targeted treatment of the fibrotic sequelae of Graves’ orbitopathy. Eye (Lond) 2019;33:679-82.
57. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003;35:7S-14S.
58. Zhang L, Grennan-Jones F, Draman MS, Lane C, Morris D, Dayan CM, et al. Possible Targets for Nonimmunosuppressive Therapy of Graves’ Orbitopathy. J Clin Endocrinol Metab. 2014;99:1183-90.
59. Roos JCP, Eglitis V, Murthy R. Inhibition of fibrotic contraction by sirolimus (Rapamycin) in an ex vivo model of thyroid eye disease. Ohthalmic Plast Reconstr Surg. 2021;37:366-71.
60. Krause G, Eckstein A, Schülein R. Modulating TSH receptor signaling for therapeutic benefit. Eur Thyroid J. 2020;9:66-77.
61. Jinhai Y, Qassem AAM, Qi J, Chao X, Anan W, Qi X, et al. Bayesian network analysis of drug treatment strategies for thyroid associated ophthalmopathy. Int Ophthalmol. 2024;44:339.
62. Scarabosio A, Surico PL, Singh RB, Tereshenko V, Musa M, D’Esposito F, et al. Thyroid eye disease: Advancements in orbital and ocular pathology management. J Pers Med. 2024;14:776.
63. Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, Perez-Pampin E, Romo Lopez A, Rodriguez Alvarez FM, et al. Tocilizumab in Graves orbitopathy study G. Efficacy of tocilizumab in patients with moderate-tosevere corticosteroid-resistant Graves orbitopathy: A randomized clinical trial. Am J Ophthalmol. 2018;195:181-90.
64. Salvi M, Vannucchi G, Currò N, Campi I, Covelli D, Dazzi D, et al. Efficacy of B-Cell Targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: A randomized controlled study. J Clin Endocrinol Metab. 2015;100:422-31.
65. Bennedjaï A, Bouheraoua N, Gatfossé M, Dupasquier-Fediaevsky L, Errera MH, Tazartes M, et al. Tocilizumab versus rituximab in patients with moderate to severe steroid-resistant Graves' orbitopathy. Ocul Immunol Inflamm. 2022;30:500-5.
66. Sharma A, Stan MN, Rootman DB. Measuring health-related quality of life in thyroid eye disease. J Clin Endocrinol Metab. 2022;107:27-35.
67. Salvi M, Campi I. Medical treatment of Graves' Orbitopathy. Horm Metab Res. 2015;47:779-88.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
